Envista Holdings Corporation Common stock, $0.01 par value per share
NVST
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.
Last trade$23.70
Day change-$0.33 (-1.37%)
Day range$23.50 – $24.31
Volume1,635,467
Market cap$3.85B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.85B
Price / earnings
6.08×
Price / book
1.25×
Price / sales
1.34×
EV / sales
1.43×
EV / EBITDA
9.94×
Profitability
Earnings per share
$3.95
Return on assets
11.29%
Return on equity
20.51%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.46×
Current ratio
2.45×
Quick ratio
2.1×
Cash ratio
1.42×
Cash flow
Price / cash flow
12.77×
Price / free cash flow
15.92×
Free cash flow
$242M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NVST, quarterly periods
Line item
Q3 FY2026 Oct 2, 2026
Q2 FY2026 Jul 3, 2026
Q1 FY2026 Apr 3, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 26, 2025
Q2 FY2025 Jun 27, 2025
Q1 FY2025 Mar 28, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$691.5M
$730.5M
$705.5M
$750.6M
$669.9M
$682.1M
$616.9M
$652.9M
Cost of revenue
$290.9M
$323.5M
$315.4M
$340M
$299.7M
$312.2M
$280.9M
$280.4M
Gross profit
$400.6M
$407M
$390.1M
$410.6M
$370.2M
$369.9M
$336M
$372.5M
Selling, general and administrative
$284.2M
$296.3M
$297.6M
$305.2M
$284.4M
$295.3M
$271.7M
$299.7M
Research and development
$29.3M
$30.4M
$30M
$32.1M
$28.3M
$28.3M
$25.3M
$26.7M
Total operating expenses
$313.5M
$326.7M
$327.6M
$337.3M
$312.7M
$323.6M
$297M
$326.4M
Operating income
$87.1M
$80.3M
$62.5M
$73.3M
$57.5M
$46.3M
$39M
$46.1M
Interest expense
-$7.8M
-$8.7M
-$7.4M
$0
-$9M
-$8M
-$9.3M
$0
Income before taxes
$500.2M
$74.4M
$52.2M
$57.6M
$49.9M
$40.7M
$29M
$36.5M
Income taxes
-$8.1M
$20.7M
$13.5M
$24.7M
$80.2M
$14.3M
$11M
$35.3M
Net income
$508.3M
$53.7M
$38.7M
$32.9M
-$30.3M
$26.4M
$18M
$1.2M
Net income attributable to common shareholders
$508.3M
$53.7M
$38.7M
$32.9M
-$30.3M
$26.4M
$18M
$1.2M
EBITDA
$112.5M
$108.1M
$91.7M
$102.4M
$86.7M
$76.1M
$66.9M
$73.9M
Basic earnings per share
$3.16
$0.33
$0.24
$0.20
-$0.18
$0.16
$0.10
$0.01
Diluted earnings per share
$3.11
$0.33
$0.23
$0.20
-$0.18
$0.16
$0.10
$0.01
Recent news
Company coverage with links to the original publishers.
Envista Holdings (NVST) has gained 24% over the past year, outperforming its industry, driven by international expansion, new product launches, and strong earnings beats. The company achieved 9% adjusted EBITDA growth and 25% EPS growth. However, fierce competition, weakness in China sales, and foreign exchange headwinds pose risks to future revenue and margin expansion.
Zacks Premium provides investors with research tools including the Zacks Rank stock-rating system and Style Scores (Value, Growth, Momentum, and VGM) to identify stocks with the best chance of outperforming the market. The Zacks Rank #1 stocks have averaged +23.82% annual returns since 1988, more than double the S&P 500. Envista (NVST) is highlighted as a stock to watch with a #3 Hold rank and B VGM Score, showing positive momentum with shares up 9.9% over four weeks.
Envista Holdings (NVST) raised its 2026 adjusted EPS guidance to $1.54-$1.58 and EBITDA growth outlook to 12.5%-14% following strong Q3 results with 25% earnings growth. However, China's upcoming volume-based procurement reforms threaten to cut orthodontics prices by 50% and implant prices by 10%-15% in 2027, pressuring future margins despite management's confidence in margin expansion outside China.
Envista (NVST) reported Q3 2026 revenue of $691.5 million, up 3.2% year-over-year, beating consensus estimates by 0.76%. EPS of $0.40 exceeded expectations of $0.35 by 14.29%. The company showed mixed performance across segments, with Equipment & Consumables beating estimates while Specialty Products & Technologies slightly missed on operating profit. The stock has a Zacks Rank #3 (Hold) rating.
Envista (NVST) reported Q3 earnings of $0.40 per share, beating consensus estimates of $0.35, with revenues of $691.5 million slightly exceeding expectations. The company has outperformed the market by 14.1% year-to-date. However, the stock received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market. The Medical-Products industry ranks in the bottom 37% of Zacks industries.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.